BLASUBCUTANEOUSSYRINGE
Approved
Oct 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug Shortage Active
PEGASYS is currently in shortage. Reason: Limited Availability. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
PEGASYS (peginterferon alfa-2a) by Adienne Pharma and Biotech is alfa-2a is an inducer of the innate antiviral immune response [see ] . First approved in 2002.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PEGASYS (peginterferon alfa-2a) is a long-acting interferon alpha therapeutic administered via subcutaneous injection that induces innate antiviral immune responses. Approved in 2002, it is a mature biologic with declining market relevance as newer antivirals have superseded its use in hepatitis C and other viral indications.
$0.151MPart D
LOE ApproachingMinimal commercial activity with only 53 Medicare Part D claims in 2023 signals a sunset-phase product with skeletal team infrastructure.
Mechanism of Action
alfa-2a is an inducer of the innate antiviral immune response [see ] .
Pharmacologic Class:
Interferon alpha
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration
Started Sep 2015
277 enrolled
Healthy Volunteers
Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults
Started Mar 2015
253 enrolled
Chronic Hepatitis B
An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study
Started Dec 2014
50 enrolled
Hepatitis B, Chronic
An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C
Started Nov 2014
7,500 enrolled
Hepatitis C, Chronic
REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection
Started Sep 2014
12 enrolled
Chronic HBV Infection (HBeAg Negative)
Worked on PEGASYS at Adienne Pharma and Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.